FDA rebuffs Amneal's Parkinson's prospect with $500M peak sales target
Fierce Pharma
JULY 5, 2023
Amneal Pharmaceuticals’ hopes for a midyear launch of its extended-release Parkinson’s disease prospect—and a shot at a potential $500 million peak sales opportunity in the U.S.—have
Let's personalize your content